Check CNCT19 cell therapy for relapsed childhood ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent/guardian (and the patient when appropriate) can sign consent before any study tests
- Age 3 to 18 years and weight at least 10 kg
- Your leukemia is relapsed or refractory acute lymphoblastic leukemia (ALL)
- Recent proof the leukemia cells have CD19 (tested in blood or bone marrow within 3 months)
- Bone marrow test at screening shows at least 5% leukemia blast cells
- You do not have certain exclusions like active CNS leukemia, serious ongoing infections, or prior CAR-T
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.